Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical timolol eye drops for facial rosacea
IRCT20220110053685N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rosacea comparing Timolol arm with Placebo arm (2 arms). Primary endpoints: Erythema, Flushing and 1 more. Started Jan 2022; status: completed.
02
Drugs
timolol
03
Conditions
rosacea
Beyond the preview
Go deeper on IRCT20220110053685N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220110053685N1.